Versant Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Versant Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$116K	Sell	1,460 -95	-6%	-$7.15K	0.01%	855
2026 Q1	$117K	Buy	1,555 +59	+4%	+$4.66K	0.01%	802
2025 Q4	$118K	Buy	1,496 +31	+2%	+$2.33K	0.01%	682
2025 Q3	$95.8K	Hold	1,465	–	–	0.01%	727
2025 Q2	$57.9K	Buy	1,465 +1,364	+1,350%	+$44.6K	0.01%	910
2025 Q1	$3.05K	Buy	101 +46	+84%	+$1.51K	﹤0.01%	2195
2024 Q4	$1.92K	Sell	55 -8	-13%	-$299	﹤0.01%	2068
2024 Q3	$2.52K	Buy	63 +8	+15%	+$372	﹤0.01%	1507
2024 Q2	$2.62K	Sell	55 -4	-7%	-$164	﹤0.01%	1436
2024 Q1	$2.56K	Hold	59	–	–	﹤0.01%	1270
2023 Q4	$2.98K	Sell	59 -7	-11%	-$335	﹤0.01%	1158
2023 Q3	$2.99K	Hold	66	–	–	﹤0.01%	1162
2023 Q2	$2.71K	Buy	66 +4	+6%	+$154	﹤0.01%	1264
2023 Q1	$2.21K	Sell	62 -16	-21%	-$601	﹤0.01%	1250
2022 Q4	$2.95K	Hold	78	–	–	﹤0.01%	1047
2022 Q3	$3K	Hold	78	–	–	﹤0.01%	986
2022 Q2	$3K	Hold	78	–	–	﹤0.01%	993
2022 Q1	$3K	Buy	78 +32	+70%	+$1.05K	﹤0.01%	1037
2021 Q4	$1K	Sell	46 -7	-13%	-$220	﹤0.01%	1277
2021 Q3	$2K	Buy	53 +7	+15%	+$264	﹤0.01%	1134
2021 Q2	$2K	Hold	46	–	–	﹤0.01%	1132
2021 Q1	$2K	Hold	46	–	–	﹤0.01%	1245
2020 Q4	$2K	Hold	46	–	–	﹤0.01%	1127
2020 Q3	$2K	Hold	46	–	–	﹤0.01%	1071
2020 Q2	$2K	Hold	46	–	–	﹤0.01%	1063
2020 Q1	$2K	Hold	46	–	–	﹤0.01%	1012
2019 Q4	$2K	Hold	46	–	–	﹤0.01%	1146
2019 Q3	$2K	Hold	46	–	–	﹤0.01%	1169
2019 Q2	$2K	Hold	46	–	–	﹤0.01%	1182
2019 Q1	$3K	Hold	46	–	–	﹤0.01%	1251
2018 Q4	$2K	Hold	46	–	–	﹤0.01%	1247
2018 Q3	$2K	Hold	46	–	–	﹤0.01%	1296
2018 Q2	$1K	Sell	46 -11	-19%	-$488	﹤0.01%	1395
2018 Q1	$2K	Sell	57 -129	-69%	-$6.55K	﹤0.01%	1276
2017 Q4	$9K	Hold	186	–	–	﹤0.01%	944
2017 Q3	$9K	Sell	186 -30	-14%	-$1.57K	﹤0.01%	890
2017 Q2	$10K	Hold	216	–	–	0.01%	867
2017 Q1	$8K	Hold	216	–	–	﹤0.01%	914
2016 Q4	$10K	Hold	216	–	–	0.01%	824
2016 Q3	$7K	Sell	216 -26	-11%	-$813	﹤0.01%	913
2016 Q2	$5K	Hold	242	–	–	﹤0.01%	963
2016 Q1	$9K	Sell	242 -29	-11%	-$1.18K	0.01%	790
2015 Q4	$16K	Buy	+271	New	+$14.6K	0.01%	583

Other funds holding IONS

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Westmount Partners Los Angeles, California $457M AUM 31.05% 1-Year Est. Return

Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

SWP

Significant Wealth Partners Cary, Illinois $92.4M AUM 9.22% 1-Year Est. Return

Cypress Capital Franklin, Tennessee $370M AUM 16.36% 1-Year Est. Return

Versant Capital Management's IONS Position: Q2 2026 in Review

Versant Capital Management reduced its Ionis Pharmaceuticals (IONS) stake by 6.1% in Q2 2026, selling an estimated $7.15K and leaving 1,460 shares worth $116K. The position accounts for 0.01% of the portfolio, ranked #855.

Versant Capital Management first reported a position in IONS in Q4 2015 and has held it in 43 quarters since. The position peaked at $118K in Q4 2025. 53 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Versant Capital Management held 1,460 shares of Ionis Pharmaceuticals worth $116K as of Q2 2026.
Versant Capital Management sold 95 Ionis Pharmaceuticals shares in Q2 2026, an estimated $7.15K.
Ionis Pharmaceuticals made up 0.01% of Versant Capital Management's portfolio in Q2 2026, its #855 holding.
Versant Capital Management first reported a position in Ionis Pharmaceuticals in Q4 2015 and has held it in 43 quarters since.
Versant Capital Management's Ionis Pharmaceuticals position peaked at $118K in Q4 2025.
53 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.